On May 1, 2024, Thomas Krummel, Director at PROCEPT BioRobotics Corp (PRCT, Financial), sold 20,000 shares of the company. The transaction was filed on the same day with the SEC. Over the past year, the insider has sold a total of 40,000 shares and has not made any purchases.
PROCEPT BioRobotics Corp (PRCT, Financial) is a medical device company that focuses on designing, developing, and commercializing innovative surgical robotic systems for use in minimally invasive surgery. The company's flagship product, the AquaBeam Robotic System, utilizes proprietary waterjet technology to enable precise, automated tissue removal for the treatment of benign prostatic hyperplasia (BPH).
On the day of the sale, shares of PROCEPT BioRobotics Corp were priced at $60, resulting in a market cap of approximately $3.31 billion. This valuation reflects the company's standing and investor expectations in the medical technology market.
The insider transaction history for PROCEPT BioRobotics Corp shows a trend of more insider sales than purchases over the past year, with 24 insider sells and no insider buys. This pattern can be observed in the insider trend image below:
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors may refer to the respective links.
This sale by the insider could be part of personal financial management or portfolio adjustments. Investors often monitor insider behaviors such as this to gain insights into potential company performance and strategic shifts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
